LncRNA as a Therapeutic Target for Angiogenesis
نویسندگان
چکیده
منابع مشابه
LncRNA as a Therapeutic Target for Angiogenesis
BACKGROUND Out of 3 billion base pairs in human genome only ~2% code for proteins; and out of 180,000 transcripts in human cells, about 20,000 code for protein, remaining 160,000 are non-coding transcripts. Most of these transcripts are more than 200 base pairs and constitute a group of long non-coding RNA (lncRNA). Many of the lncRNA have its own promoter, and are well conserved in mammals. Ac...
متن کاملAngiogenesis as a therapeutic target in endometriosis.
INTRODUCTION Angiogenesis is a key factor for the successful establishment and growth of endometriotic lesions. MATERIAL AND METHODS We performed a literature search in PubMed and reviewed the most pertinent studies published until January 2014 and focused on the endometriosis-associated angiogenesis and/or anti-angiogenic strategies for the treatment of this gynecological disorder. RESULTS...
متن کاملAngiogenesis as a therapeutic target in cancer.
Clinical Medicine Vol 8 No 4 August 2008 455 © Royal College of Physicians, 2008. All rights reserved. New blood vessel formation (angiogenesis) is a physiological process which is active in embryogenesis, in adults during wound healing and in the female reproductive cycle. Physiologically, it is a tightly regulated and transient process under the control of a host of proand anti-angiogenic fac...
متن کاملDll4-Notch signaling as a therapeutic target in tumor angiogenesis
Tumor angiogenesis is an important target for cancer therapy, with most current therapies designed to block the VEGF signaling pathway. However, clinical resistance to anti-VEGF therapy highlights the need for targeting additional tumor angiogenesis signaling pathways. The endothelial Notch ligand Dll4 (delta-like 4) has recently emerged as a critical regulator of tumor angiogenesis and thus as...
متن کاملAngiogenesis as a therapeutic target in malignant gliomas.
Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging efficacy and tolerability in preliminary clinical trials suggest that targeting angiogenesis may be an effective therapeutic strategy ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Topics in Medicinal Chemistry
سال: 2017
ISSN: 1568-0266
DOI: 10.2174/1568026617666161116144744